



## Broadview Ventures Appoints Cardiovascular Leader and MedTech Executive Ian Meredith, MBBS, PhD to its Strategic Advisory Board

**BOSTON – September 8, 2025** – Broadview Ventures, a mission-driven investment firm dedicated to accelerating the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke, today announced the appointment of Ian Meredith, MBBS, PhD, to its Strategic Advisory Board. Dr. Meredith is an internationally recognized interventional cardiologist, clinical trialist, and MedTech executive with decades of experience in healthcare and innovation.

Dr. Meredith is the former Executive Vice President and Global Chief Medical Officer for Boston Scientific, where he led clinical innovation, pre-clinical science, and medical affairs across the global organization and provided leadership for the company's clinical trials and R&D strategy.

Prior to joining Boston Scientific in 2017, Dr. Meredith served as Professor & Director of MonashHeart, an internationally recognized cardiology service within Monash Health in Melbourne, Australia. He conceived of and developed the concept for the Victorian Heart Hospital in 2005, Australia's first purpose-built, dedicated, stand-alone, technologically advanced heart hospital. He is currently a Vice Chancellor's Professorial Fellow at Monash University and a Non-Executive director serving on the boards of U.S. and Australian private and public companies.

Dr. Meredith is globally-renowned for bringing world-leading translational research into clinical practice. He has mentored and fostered the careers of a generation of academic and clinical cardiologists and has performed more than 20,000 invasive cardiac and coronary procedures. He has championed new treatment paradigms into daily clinical practice and has served as the principal investigator on many major international, multi-center, randomized trials, including several global first-in-human studies.

"We are thrilled to add an experienced cardiovascular and MedTech industry leader of Ian's caliber to our Strategic Advisory Board," said Christopher Colecchi, Managing Director of Broadview Ventures. "We look forward to leveraging his vast expertise and insights as we continue to advance our mission-driven approach to investing and supporting companies focused on bringing innovative technologies to patients in need."

Dr. Meredith has published more than 500 peer-reviewed scientific manuscripts, delivered more than 500 invited lectures internationally and presented as the first

operator on numerous live-case operation broadcasts from MonashHeart to most of the leading international clinical conferences globally.

In 2012, Dr. Meredith received an Order of Australia (AM) for outstanding service to medicine in the field of Cardiology. In 2019, he received a Doctor of Laws, Honoris Causa, for outstanding service to Monash University.

“I am excited to support Broadview Ventures’ mission and dedication to improve the lives of patients with cardiovascular disease,” said Dr. Meredith. “I look forward to contributing to Broadview’s important efforts to advance the field through targeted investments in high impact science.”

### **About Broadview Ventures**

Broadview Ventures is a mission-driven investment organization that makes targeted investments in early-stage companies to accelerate the development of innovative therapeutics, devices, and diagnostics for cardiovascular disease and stroke. Broadview is funded by The Leducq Charitable Trust.

To learn more about Broadview's portfolio and activities, please visit our [website](#).

Broadview Ventures | 265 Franklin Street | Boston, MA 02110 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!